Article Text

other Versions


Markov model into the cost-utility over five years of etanercept and infliximab compared to usual care in patients with active ankylosing spondylitis

Statistics from

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.